<DOC>
	<DOC>NCT00702520</DOC>
	<brief_summary>The objective of this trial is to evaluate whether corifollitropin alfa (MK-8962, Org 36286) treatment for the induction of multifollicular growth in women undergoing Controlled Ovarian Stimulation (COS) prior to in vitro fertilization (IVF) or Intracytoplasmic Sperm Injection (ICSI) is safe for pregnant participants and their offspring.</brief_summary>
	<brief_title>Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial 38833 (P05783)</brief_title>
	<detailed_description>This is a follow-up protocol to prospectively monitor pregnancy, delivery, and neonatal outcomes of all women who were treated with corifollitropin alfa and became pregnant during the base Trial 38833. For this follow-up trial (38834), no investigational products will be administered and no study specific assessments are required, but information will be obtained as per standard clinical practice.</detailed_description>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Follicle Stimulating Hormone</mesh_term>
	<mesh_term>Triptorelin Pamoate</mesh_term>
	<criteria>Participants who received one dose of corifollitropin alfa in Trial 38833; Ongoing pregnancy confirmed by ultrasound at least 10 weeks after embryo transfer in Trial 38833; Able and willing to give written informed consent.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>39 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Neonatal outcome</keyword>
	<keyword>Congenital malformations</keyword>
	<keyword>In-Vitro fertilization</keyword>
	<keyword>Controlled ovarian stimulation</keyword>
	<keyword>Follow-up</keyword>
</DOC>